Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis

被引：0

作者：

Mukhtar, Humza ^{[1
]}

Yasmeen, Uzma ^{[2
]}

Siddiqa, Sania ^{[3
]}

Sarfraz, Zouina ^{[4
]}

Sarfraz, Azza ^{[5
]}

机构：

[1] Independent Med Coll, Faisalabad, Pakistan

[2] Faisalabad Med Univ, Faisalabad, Pakistan

[3] Ameer Ud Din Med Coll, Lahore, Pakistan

[4] Fatima Jinnah Med Univ, Lahore 54000, Punjab, Pakistan

[5] Aga Khan Univ, Karachi, Pakistan

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2022年 / 65卷

关键词：

Ublituximab; Teriflunomide; Multiple sclerosis; Relapsing; Clinical trial;

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Ublituximab is an anti-CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis (MS). With limited therapeutics available, this original meta-analysis seeks to determine the effect size (using RevMan 5.4.1) for annualized relapse rate (ARR), MRI outcomes and no evidence of disease activity (NEDA) by two years post-initiation of Ublituximab. Two RCTs (N = 1094) reveal Cohen's d for ARR= -0.17 (P = 0.006) favoring Ublituximab. MRI-tested, week 96 findings of T1 (Cohen's d= -0.43, P < 0.00001) and T2 (Cohen's d= -0.55; P < 0.00001) lesions favor Ublituximab compared to Teriflunomide. Less disease activity was reported in the Ublituximab group (OR=3.33, P < 0.00001). Further trials are required to corroborate findings.

引用

页数：10

共 50 条

[1] Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis
Mukhtar, Humza
Yasmeen, Uzma
Siddiqa, Sania
Sarfraz, Zouina
Sarfraz, Azza
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 65
[2] Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
Steinman, Lawrence
Fox, Edward
Hartung, Hans-Peter
Alvarez, Enrique
Qian, Peiqing
Wray, Sibyl
Robertson, Derrick
Huang, DeRen
Selmaj, Krzysztof
Wynn, Daniel
Cutter, Gary
Mok, Koby
Hsu, Yanzhi
Xu, Yihuan
Weiss, Michael S.
Bosco, Jenna A.
Power, Sean A.
Lee, Lily
Miskin, Hari P.
Cree, Bruce A. C.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (08): : 704 - 714
[3] The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?
Doggrell, Sheila A.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (11) : 1339 - 1343
[4] Ublituximab (Briumvi) for Relapsing Multiple Sclerosis
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1671): : 36 - 38
[5] Dimethyl Fumarate or Teriflunomide for Relapsing–Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies
Luca Prosperini
Shalom Haggiag
Serena Ruggieri
Carla Tortorella
Claudio Gasperini
Neurotherapeutics, 2023, 20 : 1275 - 1283
[6] Dimethyl Fumarate or Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies
Prosperini, Luca
Haggiag, Shalom
Ruggieri, Serena
Tortorella, Carla
Gasperini, Claudio
NEUROTHERAPEUTICS, 2023, 20 (05) : 1275 - 1283
[7] The efficacy and safety of teriflunomide based therapy in patients with relapsing multiple sclerosis: A meta-analysis of randomized controlled trials
Xu, Min
Lu, Xuesheng
Fang, Jing
Zhu, Xiaoqi
Wang, Jie
JOURNAL OF CLINICAL NEUROSCIENCE, 2016, 33 : 28 - 31
[8] Ublituximab versus teriflunomide in relapsing multiple sclerosis (RMS): Results of the Phase 3 ULTIMATE I and II trials
Steinman, L.
Fox, E.
Hartung, H.
Alvarez, E.
Qian, P.
Wray, S.
Robertson, D.
Huang, D.
Selmay, K.
Wynn, D.
Weiss, M.
Bosco, J.
Power, S.
Mok, K.
Cree, B.
EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 121 - 121
[9] Retrospective analysis of natalizumab switches to ublituximab in patients with relapsing multiple sclerosis
Kutz, Christen
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1074 - 1075
[10] NEDA-4 with ublituximab versus teriflunomide in the ULTIMATE I and II studies in participants with relapsing multiple sclerosis
Alvarez, E.
Steinman, L.
Hartung, H. -P.
Fox, E. J.
Qian, P.
Wray, S.
Robertson, D.
Huang, D.
Selmaj, K.
Wynn, D.
Bosco, J. A.
Campagnolo, D.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 602 - 603

← 1 2 3 4 5 →